Despite the unsatisfactory results of PSMA RLT in HCC treatment, given the lack of effective therapeutic options for patients with advanced HCC, large-sample prospective studies remain warranted to validate its therapeutic value and potential synergistic effects when combined with other therapeutic modalities. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.